Broyhill Asset Management, a boutique investment firm, released its fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. The past two years were mirror images of each other for equity investors. Global stocks increased by 22% in 2022 after declining by 18% the year before. The fourth quarter saw exceptionally high portfolio […]
(Bloomberg) Novo Nordisk A/S diabetes drug Ozempic showed surprisingly early effectiveness in a kidney-failure study, sending shares of the world’s biggest dialysis providers tumbling.Most Read from BloombergIsrael Latest: Sirens Sound in North, Biden Speaks to NetanyahuIsrael Latest: Israeli Death Toll in Hamas Attack Reaches 1,200Israel Forms Emergency Government for War Against HamasHamas Got Around Israel’s Surveillance Prowess by Going DarkIMF Caught Off Guard as China Strikes Sri Lanka
Fresenius Medical Care AG & Co. KGaA(NYSE:FMS): The coronavirus pandemic has accelerated innovations and the adoption of advanced technologies in the healthcare sector. Moreover, national healthcare spending in the United States has increased significantly. The healthcare market is growing and shows promising prospects. Healthcare stocks Fresenius Medical (FMS), Encompass Health (EHC), and Taro Pharmaceutical (TARO) have declined more than 20% year-to-date but could rebound in the coming year.